Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients

BMC Cancer

Table 3 Impact of liver steatosis on patient outcomes

*Variables*	*Synchronous metastases* (n = 283 patients; n = 42 metastases)			*Metachronous metastases* (n = 241 patients; n = 26 metastases)			*Overall survival* (n = 283 patients; n = 152 deaths)			*Overall survival excluding patients with baseline liver metastases* (n = 241 patients; n = 73 deaths)
*Variables*	OR	*95%CI*	p	HR	*95%CI*	p	HR	*95%CI*	p	HR	*95%CI*	P
Liver steatosis	1.58	0.79–3.14	0.20	1.25	0.55–2.85	0.60	0.92	0.64–1.32	0.65	0.66	0.35–1.22	0.19
Age at diagnosis	1.01	0.99–1.04	0.43	0.99	0.97–1.02	0.61	1.03	1.01–1.04	< 0.001	1.05	1.03–1.07	< 0.001
Sex	0.90	0.45–1.77	0.75	1.66	0.76–3.66	0.21	1.03	0.74–1.44	0.89	0.76	0.43–1.36	0.36
Stage	–	–	–	1.78	1.00–3.20	0.05	2.15	1.76–2.62	< 0.001	2.51	1.64–3.82	< 0.001
Year of diagnosis	1.01	0.85–1.19	0.91	0.88	0.73–1.08	0.22	0.98	0.90–1.06	0.64	0.82	0.71–0.94	0.006

Logistic multivariate models for liver metastasis presence at baseline (model includes patients with liver metastases at baseline) and Cox proportional hazards regression models for occurrence of liver metastases during follow-up (after exclusion of patients with baseline liver metastases) and for overall survival (both including all patients and after exclusion of patients with baseline liver metastases). The variable of interest was steatosis at baseline; adjusting variables (age, sex, stage, and calendar period) included in the models were selected a priori for their known impact on disease. TNM stage refers to clinical staging.

ISSN: 1471-2407